Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Basal­zell­kar­zi­nom
Cemiplimab, Libtayo, PD-1, Sonidegib, Odomzo, Hh, Vismodegib, Erivedge
Cholangio­­kar­­zi­nom
Durvalumab, Imfinzi, PD-L1, Futibatinib, Lytgobi, FGF(R), Ivosidenib, Tibsovo, IDH1, Pemigatinib, Pemazyre
Kolo­rektal­kar­zinom (CRC)
Kolorektalkarzinom, Aflibercept, Zaltrap, VEGF(R), PIGF, Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, Cetuximab, Erbitux, EGF(R), Encorafenib, Braftovi, BRAF, Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Panitumumab, Vectibix, Pembrolizumab, Keytruda, Ramucirumab, Cyramza, Regorafenib, Stivarga, KIT, RET, PDGF(R), FGF(R)
Endometrium­kar­zi­nom
Dostarlimab, Jemperli, PD-1, Lenvatinib, Kisplyx, Lenvima, VEGF(R), FGF(R), PDGF(R), KIT, RET, Pembrolizumab, Keytruda
Gastrointestinale Stromatumoren (GIST)
Gastrointestinale Stromatumoren, CD117-positiv, Avapritinib, Ayvakyt, PDGF(R), KIT, Regorafenib, Stivarga, VEGF(R), RET, BRAF, FGF(R), Ripretinib, Qinlock, TIE2, Sunitinib, Sutent, Sunitinib Accord
Hepatozelluläres Karzinom (HCC)
Hepatozelluläres Karzinom, Atezolizumab, Tecentriq, PD-L1, Cabozantinib, Cabometyx, Cometriq, MET, VEGF(R), RET, KIT, ROS, Durvalumab, Imfinzi, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Ramucirumab, Cyramza, Regorafenib, Stivarga, BRAF, Sorafenib, Nexavar, Tremelimumab, Imjudo, Tremelimumab AstraZeneca, CTLA-4
Magen, GEJ, Ösophagus
Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda, Ramucirumab, Cyramza, VEGF(R), Trastuzumab, Herceptin, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac, HER2, Trastuzumab-Deruxtecan, Enhertu
Klein­zelliges Bronchial­­kar­­zi­nom (SCLC)
Atezolizumab, Tecentriq, PD-L1, Durvalumab, Imfinzi
Kutanes Platten­epithel­kar­zinom
Mammakarzinom (MCa)
MCa, Abemaciclib, Verzenios, CDK4/6, Alpelisib, Piqray, PI3Kα, Atezolizumab, Tecentriq, PD-L1, Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, VEGF(R), Everolimus, Afinitor, mTOR, Lapatinib, Tyverb, EGF(R), HER2, Neratinib, Nerlynx, Olaparib, Lynparza, PARP, Palbociclib, Ibrance, Pembrolizumab, Keytruda, PD-1, Pertuzumab, Perjeta, Phesgo (Pertuzumab + Trastuzumab), Pertuzumab, Ribociclib, Kisqali, Sacituzumab Govitecan, Trodelvy, Trop-2, Talazoparib, Talzenna, Trastuzumab, Herceptin, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac, Trastuzumab, Trastuzumab Emtansin, Kadcyla, Trastuzumab Emtansin, Trastuzumab-Deruxtecan, Enhertu, Tucatinib, Tukysa
Merkel­zell­kar­zinom (MCC)
Merkelzellkarzinom, Avelumab, Bavencio, PD-L1
Melanom
Binimetinib, Mektovi, MEK, Cobimetinib, Cotellic, Dabrafenib, Tafinlar, BRAF, Encorafenib, Braftovi, Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda, Relatlimab, Opdualag, LAG-3, Tebentafusp, Kimmtrak, CD3, gp100-Peptid, Trametinib, Mekinist, Vemurafenib, Zelboraf
Neuroendokrine Tumoren (NET)
Neuroendokrine Tumoren, Everolimus, Afinitor, mTOR, Everolimus, Sunitinib, Sutent, Sunitinib Accord, PDGF(R), VEGF(R), KIT, RET
Nicht­klein­zelliges Bron­chial­kar­zinom (NSCLC)
Nichtkleinzelliges Bronchialkarzinom, Afatinib, Giotrif, EGF(R), HER2, Alectinib, Alecensa, ALK, RET, Amivantamab, Rybrevant, MET, Atezolizumab, Tecentriq, PD-L1, Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, VEGF(R), Brigatinib, Alunbrig, ROS1, IGF-1R, Capmatinib, Tabrecta, Cemiplimab, Libtayo, PD-1, Ceritinib, Zykadia, Crizotinib, Xalkori, ROS, Dabrafenib, Tafinlar, BRAF, Dacomitinib, Vizimpro, Durvalumab, Imfinzi, Entrectinib, Rozlytrek, TRK, Erlotinib, Tarceva, Gefitinib, Iressa, Gefitinib Mylan, Ipilimumab, Yervoy, CTLA-4, Lorlatinib, Lorviqua, Nintedanib, Vargatef, PDGF(R), FGF(R), Nivolumab, Opdivo, Osimertinib, Tagrisso, Pembrolizumab, Keytruda, Pralsetinib, Gavreto, Ramucirumab, Cyramza, Selpercatinib, Retsevmo, Sotorasib, Lumykras, KRAS G12C, Tepotinib, Tepmetko, Trametinib, Mekinist, MEK, Trastuzumab-Deruxtecan, Enhertu, Tremelimumab, Imjudo, Tremelimumab AstraZeneca
Ovarial-, Tuben-, Peritoneal­kar­zinom
Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, VEGF(R), Niraparib, Akeega (Niraparib/Abirateronacetat), Zejula, PARP, Olaparib, Lynparza, Rucaparib, Rubraca
Pankreas­karzinom
Erlotinib, Tarceva, EGF(R), Olaparib, Lynparza, PARP
Pleurameso­theliom
Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1
Prostatakarzinom
Lutetium(Lu-177)vipivotidtetraxetan, Pluvicto, PSMA, Olaparib, Lynparza, PARP
Nieren­zell­kar­zi­nom (RCC)
Nierenzellenkarzinom, renal cell carcinoma, Avelumab, Bavencio, PD-L1, Axitinib, Inlyta, VEGF(R), Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, Cabozantinib, Cabometyx, Cometriq, MET, RET, KIT, ROS, Everolimus, Afinitor, mTOR, Ipilimumab, Yervoy, CTLA-4, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Nivolumab, Opdivo, PD-1, Pazopanib, Votrient, Pembrolizumab, Keytruda, Sorafenib, Nexavar, BRAF, Sunitinib, Sutent, Sunitinib Accord, Temsirolimus, Torisel, Tivozanib, Fotivda
Kopf-Hals-Tumoren (SCCHN)
Kopf-Hals-Tumoren, Cetuximab, Erbitux, EGF(R), Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda
Schild­drüsen­kar­zi­nom
Cabozantinib, Cabometyx, Cometriq, MET, VEGF(R), RET, KIT, ROS, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Selpercatinib, Retsevmo, Sorafenib, Nexavar, BRAF, Vandetanib, Caprelsa, EGF(R)
Urothelkarzinom
Atezolizumab, Tecentriq, PD-L1, Avelumab, Bavencio, Enfortumab Vedotin, Padcev, Nectin-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda
Weich­gewebs­sarkom (STS)
STS, DFSP, Imatinib, Glivec, Accord, Actavis, Teva, BCR/ABL, KIT, PDGF(R), Pazopanib, Votrient, VEGF(R)
Zervixkarzinom
Bevacizumab, Avastin, Abevmy, Aybintio, Equidacent, Mvasi, Onbevzi, Oyavas, Zirabev, VEGF(R), Cemiplimab, Libtayo, PD-1, Pembrolizumab, Keytruda
In Kooperation mit